Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: A multicentre randomized non-inferiority trial

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Massacesi, Luca ^a,b   Tramacere, Irene ^c   Amoroso, Salvatore ^d   Battaglia, Mario A ^e   Benedetti, Maria Donata ^f   Filippini, Graziella ^c   La Mantia, Loredana ^g   Repice, Anna ^b   Solari, Alessandra ^c   Tedeschi, Gioacchino ^h   Milanese, Clara ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e Associazione Italiana Sclerosi Multipla Onlus   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

^g IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO; BETA INTERFERON; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HEALTH CARE PERSONNEL; HUMAN; LOCAL ALLERGIC REACTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTEMIC ALLERGIC REACTION; TREATMENT OUTCOME; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; YOUNG ADULT;

ADULT; AZATHIOPRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS; RECURRENCE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84912137155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113371     Document Type: Article

References (32)

1. The British, Dutch MSATG. (1988) Double-masked trial of azathioprine in multiple sclerosis. british and dutch multiple sclerosis azathioprine trial group. Lancet 2: 179-183.
2. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39: 1018-1026.
3. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. (1991) The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41: 20-25.
4. Milanese C, La Mantia L, Salmaggi A, Eoli M. (1993) A double blind study on azathioprine efficacy in multiple sclerosis: Final report. J Neurol 240: 295-298.
5. Clegg A, Bryant J, Milne R. (2000) Disease-modifying drugs for multiple sclerosis: A rapid and systematic review. Health Technol Assess 4: I-iv, 1-101.
6. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051-1055.
7. Goodin DS, Frohman EM, Garmany GP, Jr, Halper J, Likosky WH, et al. (2002) Disease modifying therapies in multiple sclerosis: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 58: 169-178.
8. IFNB MSG. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB multiple sclerosis study group. Neurology 43: 655-661.
9. PRISMS. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet 352: 1498-1504.
10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 39: 285-294.
11. Paty DW, Li DK. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, doubleblind, placebo-controlled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology 43: 662-667.
12. Casetta I, Iuliano G, Filippini G. (2007) Azathioprine for multiple sclerosis. Cochrane Database Syst Rev (4) : CD003982.
13. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, et al. (2003) Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet 361: 545-552.
14. Palace J, Rothwell P. (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350: 261.
15. Etemadifar M, Janghorbani M, Shaygannejad V. (2007) Comparison of interferon beta products and azathioprine in the treatment of relapsingremitting multiple sclerosis. J Neurol 254: 1723-1728.
16. Milanese C, La Mantia L, Salmaggi A, Caputo D. (2001) Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70: 413-414.
17. Cavazzuti M, Merelli E, Tassone G, Mavilla L. (1997) Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur Neurol 38: 284-290.
18. Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicano G, et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62: 1843-1847.
19. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
20. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452.
21. CTC (2003). Cancer therapy evaluation program, common terminology criteria for adverse event, version 3.0, DCTD, NCI, NIH, DHHS.
22. Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, et al. (1999) Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry 67: 158-162.
23. Committee for medicinal product for human use (CHMP) (2005). Guideline on the choise of the non-inferiority margin. doc. ref. EMEA/CPMP/EWP/2158/99.
24. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, et al. (2006) Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295: 1152-1160.
25. Sackett DL. (2004) Superiority trials, noninferiority trials, and prisoners of the 2-sided null hypothesis. ACP J Club 140: A11.
26. Rubin DB. (1987) Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons.
27. Brand JPL. (1999) Development, implementation and evaluation of multiple imputation strategies for the statistical analysis of incomplete data sets, ph.D. Thesis, erasmus university, rotterdam.
28. van Buuren S, Boshuizen HC, Knook DL. (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18: 681-694.
29. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. (2012) Reporting of noninferiority and equivalence randomized trials: Extension of the CONSORT 2010 statement. JAMA 308: 2594-2604.
30. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, et al. (2013) Immunomodulators and immunosuppressants for multiple sclerosis: A network meta-Analysis. Cochrane Database Syst Rev 6: CD008933.
31. Schulz KF, Grimes DA. (2005) Sample size calculations in randomised trials: Mandatory and mystical. Lancet 365: 1348-1353.
32. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277-1285.